DEFA14A: Hologic Reports Strong Q4, Announces Acquisition by Blackstone & TPG

Hologic, Inc. announced robust fiscal fourth-quarter results with significant revenue and EPS growth, alongside a definitive agreement to be acquired by Blackstone and TPG for up to $79 per share.

Summary

• Hologic reported total revenue of $1,049.5 million for the fiscal fourth quarter ended September 27, 2025, an increase of 6.2% (5.4% in constant currency) compared to the prior year.
• GAAP diluted EPS increased 9.2% to $0.83, while non-GAAP diluted EPS rose 11.9% to $1.13.
• Organic revenue, excluding COVID-19 and related revenue, grew 6.2% (5.4% in constant currency).
• Diagnostics revenue was $454.1 million, up 2.4%, driven by core U.S. molecular diagnostics sales, despite lower COVID-19 assay sales and reduced sales in China.
• Breast Health revenue increased 4.8% to $393.7 million, fueled by strong interventional products sales and the inclusion of Endomagnetics.
• Surgical revenue grew 10.2% to $172.5 million, primarily due to increased sales of MyoSure and Fluent, and the acquired Gynesonics business.
• Skeletal Health revenue saw a substantial increase of 129.9% to $29.2 million.
• Cash flow from operations for the quarter was $355.1 million, and the company ended with $1.96 billion in cash and cash equivalents.
• Hologic announced a definitive agreement on October 21, 2025, to be acquired by funds managed by Blackstone and TPG in a transaction valued at up to $79 per share.
• The company received FDA clearance and CE marking for its Panther Fusion Gastrointestinal Bacterial and Expanded Bacterial Assays.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to strong financial performance in core segments, significant EPS growth, and the announcement of a proposed acquisition at a premium, which typically benefits shareholders.

Positives

• Total revenue increased 6.2% to $1,049.5 million, demonstrating strong top-line growth.
• Non-GAAP diluted EPS grew 11.9% to $1.13, indicating improved profitability.
• Organic revenue, excluding COVID-19 and related revenue, increased 6.2%, highlighting strength in core businesses.
• Surgical revenue showed robust growth of 10.2%, driven by key product lines and acquisitions.
• Interventional breast solutions revenue surged 24.5%, contributing significantly to Breast Health segment growth.
• Skeletal Health revenue experienced exceptional growth of 129.9%.
• Non-GAAP operating margin improved by 120 basis points to 31.2%, reflecting increased leverage on operating expenses.
• Strong cash flow from operations of $355.1 million and a healthy cash position of $1.96 billion.
• Low adjusted net leverage ratio of 0.4 times, indicating a strong balance sheet.
• FDA clearance and CE marking for new Panther Fusion assays expand the product portfolio and market reach.

Negatives

• GAAP gross margin decreased by 90 basis points to 55.6%, partly due to expenses from closing the Manchester manufacturing facility.
• Non-GAAP gross margin decreased by 60 basis points to 60.9%, primarily due to product mix and increased tariff expenses.
• GAAP operating margin decreased by 70 basis points to 22.6%, impacted by acquisition-related expenses and impairment/restructuring charges.
• COVID-19 revenue declined by 27.3% to $29.1 million, reflecting a decrease in demand for related products.
• Molecular diagnostics revenue growth was modest at 1.2% (0.4% constant currency), partially offset by lower sales in China and COVID-19 assays.

Risks

• Development of new or improved competitive technologies and products and general competition.
• Ability to accurately predict demand for products and develop successful market strategies.
• Effect of consolidation in the healthcare industry.
• Ability to execute acquisitions and realize anticipated benefits from completed or future acquisitions.
• Coverage and reimbursement decisions of third-party payors.
• Uncertainty of the impact of cost containment efforts and federal healthcare reform legislation.
• Ability to obtain and maintain regulatory approvals and clearances for products, including compliance with EU Medical Device and In Vitro Diagnostic Regulation requirements.
• Possibility that products may contain undetected errors or defects or otherwise not perform as anticipated.
• Impact and costs of investigative and legal proceedings and compliance risks.
• Potential negative impacts from climate change or other environmental, social, and governance matters.
• Impact of future tax legislation.
• Ongoing and possible future effects of global challenges, including macroeconomic uncertainties, inflation, bank failures, government shutdowns, rising interest rates, capital markets availability, wars, conflicts, economic disruptions, and recession concerns.
• Effect of worldwide political and social uncertainty and divisions, including impacts on trade regulations and tariffs.
• Potential cybersecurity threats and targeted computer crime.
• Ongoing and possible future effects of supply chain constraints, including availability of critical raw materials and components, and cost inflation.
• Possibility of interruptions or delays at manufacturing facilities or failure to secure alternative suppliers.
• Ability to consolidate manufacturing and other operations timely and within budget without disrupting business and achieving anticipated cost synergies.
• Ability to meet production and delivery schedules for products.
• Effect of any future public health pandemic or other crises.
• Ability to successfully manage ongoing organizational and strategic changes, attract, motivate, and retain key employees, and maintain engagement and efficiency in remote work environments.
• Ability to protect intellectual property rights.
• Anticipated trends relating to financial condition or results of operations, including interest rate and foreign currency exchange fluctuations.
• Compliance with covenants contained in debt agreements.
• Timing, receipt, and terms of governmental and regulatory approvals for the proposed acquisition by Blackstone and TPG.
• Occurrence of any event, change, or other circumstances that could give rise to the termination of the merger agreement.
• Possibility that stockholders may not approve the proposed transaction.
• Risk that parties to the merger agreement may not be able to satisfy the conditions to the proposed transaction in a timely manner or at all.
• Risks related to disruption of management time from ongoing business operations due to the proposed transaction.
• Risk that any announcements relating to the proposed transaction could have adverse effects on the market price of common stock.
• Risk of any unexpected costs or expenses resulting from the proposed transaction.
• Risk of any litigation relating to the proposed transaction.
• Risk that the proposed transaction and its announcement could have an adverse effect on the ability to retain and hire key personnel and to maintain relationships with customers, vendors, partners, employees, stockholders, and other business relationships.
• Risk that the holders of the contingent value rights (CVRs) in the proposed transaction will receive less-than-anticipated payments with respect to the CVRs after the closing of the proposed transaction.

Future Outlook

Hologic is not providing annual or quarterly financial guidance for fiscal year 2026 due to the definitive agreement to be acquired by Blackstone and TPG. The company will also not host a conference call to discuss its fourth quarter 2025 financial results.

Industry Context

Hologic operates in the medical technology sector, primarily focused on women's health. The reported strong performance in core segments like Breast Health and Surgical, coupled with growth in molecular diagnostics (excluding COVID-19), indicates resilience and effective strategy execution in key areas. The proposed acquisition by private equity firms Blackstone and TPG suggests a belief in the company's long-term value and potential for further growth or operational efficiencies under private ownership, a common trend in mature, stable industries with strong cash flows.

Corporate Governance

Stakeholder Impact

• Shareholders: The proposed acquisition at up to $79 per share offers a significant return, subject to the terms of the contingent value rights (CVRs) and deal completion.
• Employees: The closing of the Manchester, England manufacturing facility and potential integration following the acquisition may impact employees through restructuring or changes in roles.
• Customers: Continued product development and regulatory clearances (e.g., Panther Fusion assays) indicate ongoing commitment to product innovation and availability.
• Creditors: The company's low adjusted net leverage ratio of 0.4 times suggests a strong financial position, and debt refinancing was mentioned, indicating active management of liabilities.

Next Steps

• Hologic will file a Proxy Statement with the SEC in connection with the proposed acquisition.
• Hologic plans to mail a definitive Proxy Statement to its stockholders.
• Stockholders are urged to read the Proxy Statement and other relevant documents filed or to be filed with the SEC carefully as they become available.
• Hologic and its directors and executive officers may be deemed participants in the solicitation of proxies from Hologic stockholders for the proposed transaction.

Key Dates

Recommendation

The proposed acquisition by Blackstone and TPG Capital at up to $79 per share, which includes a contingent value right (CVR) component, makes the stock's short-term value largely dependent on the deal's completion and the CVR's payout. For existing shareholders, holding until the transaction closes is a reasonable strategy to realize the acquisition value. The strong Q4 results support the company's underlying value but are overshadowed by the acquisition news, making the primary investment decision tied to the merger arbitrage rather than fundamental performance.

Keywords

Hologic, HOLX, Medical Technology, Women's Health, Diagnostics, Breast Health, Surgical, Molecular Diagnostics, Acquisition, Blackstone, TPG Capital, Q4 Earnings, Financial Results, SEC Filing